A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

In by Hannah Schaffner

Locations
Condition
Hypertension

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

  • Hidden
  • This field is for validation purposes and should be left unchanged.

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication
Exclusion Criteria
  1. Secondary hypertension, orthostatic hypotension
  2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× upper limit of normal (ULN)
  3. Elevated potassium >5 mEq/L
  4. Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m^2
  5. Received an investigational agent within the last 30 days
  6. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  7. History of any cardiovascular event within 6 months prior to randomization
  8. History of intolerance to SC injection(s)
Back to Current Studies